Risk of Dementia in First-Degree Relatives of Patients With Alzheimer’s Disease and Related Disorders

Richard Mayeux, MD; Mary Sano, PhD; Jenn Chen, PhD; Thomas Tatemiichi, MD; Yaakov Stern, PhD

Several case-control* and cohort studies** provide evidence supporting a genetic cause for Alzheimer’s disease (AD). The cumulative incidence of an Alzheimer-like dementia in first-degree relatives of patients with AD may be as high as 50% by the eighth decade of life.*** Although there is a great deal of consistency in those investigations, Farrer et al.**** did not find an increased risk of dementia in first-degree relatives of patients with AD compared with the first-degree relatives of patients with Parkinson’s disease. This indicates that either the increased risk of dementia is not specific to relatives of patients with AD, or that there could be a bias in the way these studies are conducted.

We systematically recorded information about first-degree relatives at the initial visit, before the diagnosis was established, in every patient attending an urban clinic for memory disorders. We estimated the cumulative incidence of dementia in the first-degree relatives of patients with clinically diagnosed AD and other disorders, including other types of dementia, and in a group of healthy elderly control subjects. We wanted to determine whether the increased risk of dementia in first-degree relatives of patients with AD is on a genetic basis, and whether this is specific to AD or whether it is due to a selection bias because of heightened awareness in the families of patients with dementia.

PATIENTS, MATERIALS, AND METHODS

Subjects

Patients.—Data from 222 consecutive persons visiting a state-supported clinic for memory disorders during a 2-year period in the Washington Heights-Inwood neighborhood of northern Manhattan and the bordering area were used in this study. Patients were referred to the clinic by private physicians in the surrounding area, and about half were self-referred.

Before coming to the clinic, patients were screened in a semi-structured telephone interview with the responsible family member. The purpose of this interview was to exclude people younger than 30 years, or those with a lifetime history of epilepsy or primary psychiatric disorder, such as schizophrenia. Patients with Huntington’s disease, stroke, and other major neurologic diseases were also excluded by the telephone interview, where possible, and referred to other clinics.

Healthy Elderly Comparison Group.—Elderly adult volunteers were also recruited from the community. A letter was written asking the recipient to participate in a study on aging and memory. We also asked elderly relatives of patients with cerebrovascular disorders in the Presbyterian Hospital, New York, NY, and members of local senior centers to participate. No details about the study hypotheses were provided until after the subjects completed their participation in the study.

Clinical Assessment

Information regarding medical health, all medications used during the last year, history of their present illness, and both present and past psychiatric records were filed in a standardized recording format. All subjects were rated on their ability to be independent in daily activities.

All patients and healthy elderly control subjects received a physical and neurologic examination. Most patients, and all control...
subjects, received a neuropsychologic test battery. Patients with dementia were hospitalized to undergo a computed tomographic scan of the head, lumbar puncture, electroencephalogram, blood test, and neuropsychologic tests unless these procedures had been performed within the last year and were available for review.

A diagnosis for every patient and recruited subject was made after all clinical studies were completed. Each chart was then independently reviewed by two of us (R.M. and Y.S.) to render a diagnosis. The family history was not used in the diagnostic process at any level. Criteria for primary degenerative dementia were those suggested by the National Institute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group.

Family History

A semistructured family history questionnaire, similar to published versions, was used in all subjects, patients, and the responsible family members or companions, who acted as informants. The pedigree for all known first-degree relatives was recorded and reviewed at the time of data collection with the responsible informant (attendants or nursing aides were not considered as informants).

The semistructured format for the family history began with standardized questions about each first-degree relative (parents and siblings only; children of probands were excluded) to determine age, sex, position in the family, and the presence of “Alzheimer’s disease, dementia, senility, or memory loss.” Additional nonstandardized questions were used when needed to clarify the presence and type of dementia. The interview was directed to both the patient and the family member (or family members if there was more than one); disagreements between them were resolved before recording the response. The age at death and the cause of death were recorded, as was the current age if still alive when available. When a family reported dementia, follow-up questions were asked to determine whether the affected relative was still alive or now dead.

Breitner and Margruder-Habib recommended using a standard time after presumed onset to establish “caseness” and “onset,” but we did not believe that the informants or the patients could reliably estimate the date of onset of symptoms in relatives as well as in the proband. Therefore, for all groups we consistently used the current age, if alive, or the age at death reported by the proband’s informant to estimate age cumulative incidence in first-degree relatives and avoid an inaccurate estimate of disease “onset.” This approach was nondifferential to any group of subjects. The interviewer recording the pedigree was blinded to the final clinical diagnosis of the proband. Records were not used if they were incomplete or if there was some question about the quality of information.

### Table 1. — Non-Alzheimer Dementias *

<table>
<thead>
<tr>
<th>Dementias</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol related</td>
<td>5</td>
</tr>
<tr>
<td>Pick’s disease</td>
<td>3</td>
</tr>
<tr>
<td>Major depression with dementia</td>
<td>3</td>
</tr>
<tr>
<td>Head injury</td>
<td>3</td>
</tr>
<tr>
<td>Brain tumor</td>
<td>2</td>
</tr>
<tr>
<td>Focal effects of stroke</td>
<td>2</td>
</tr>
<tr>
<td>Progressive supranuclear palsy</td>
<td>1</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>1</td>
</tr>
<tr>
<td>Creutzfeldt-Jakob disease</td>
<td>1</td>
</tr>
<tr>
<td>Giant cell arteritis</td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>3</td>
</tr>
</tbody>
</table>
* N = 25.

### Database Management and Analysis

All information was entered and stored in a database (CLINFO system). Analysis of variance and statistical methods for rates and proportions were used to compare characteristics of the three groups. The SAS logistic regression was used to adjust relative-risk estimates, and the SAS product-limit survival estimates were used to estimate the cumulative incidence of dementia in the first-degree relatives. Power estimates were calculated as suggested by Cohen.

### RESULTS

#### Subjects

Two hundred twenty-two patients were evaluated in the Memory Disorders Clinic (New York, NY) during the 2-year study period. One hundred fourteen patients met the criteria for probable AD, but only 110 patients had adequate information to provide a pedigree of first-degree relatives. These 110 subjects became the AD patient group.

In the remaining 80 patients, 25 had other forms of dementia as listed in Table 1. In the other 55 patients, other neurologic problems without dementia, based on neuropsychologic testing available, were found in all but 15 patients, as noted in Table 2. Only 68 of these 80 patients had adequate information regarding family pedigree of first-degree relatives. The other 12 were excluded; six were demented and six were nondemented patients. The 68 subjects became the patient comparison group (PCG).

Table 2. — Other Disorders *

<table>
<thead>
<tr>
<th>Disorders</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with symptoms but</td>
<td></td>
</tr>
<tr>
<td>with no specific disorder</td>
<td>15</td>
</tr>
<tr>
<td>Cognitive impairment due to</td>
<td></td>
</tr>
<tr>
<td>stroke</td>
<td>9</td>
</tr>
<tr>
<td>Depression without dementia</td>
<td>7</td>
</tr>
<tr>
<td>Alcoholism</td>
<td>6</td>
</tr>
<tr>
<td>Amnesia of unknown cause</td>
<td>3</td>
</tr>
<tr>
<td>Cognitive impairment dementia</td>
<td>2</td>
</tr>
<tr>
<td>Clonal psychiatric disorder</td>
<td>2</td>
</tr>
<tr>
<td>Other disorders with mild</td>
<td></td>
</tr>
<tr>
<td>cognitive impairment but</td>
<td></td>
</tr>
<tr>
<td>without dementia</td>
<td>11</td>
</tr>
</tbody>
</table>
* N = 55.

The agreement above chance on the diagnosis of dementia for all subjects and patients by the two clinicians was substantial (for AD, $x^2 = .73$ and for cognitive disorder and all other patients, $x^2 = .68$). Any disagreement on diagnosis was resolved by two of us (R.M. and Y.S.) and a diagnosis was assigned prior to data analysis. Twenty-eight patients had AD with an associated condition that could have resulted in dementia and were classified with possible AD. We excluded these patients to be certain about the clinical diagnosis of AD and to avoid AD in the PCG. Since the development of these cohorts the diagnoses in the AD and PCG have not changed over 2 years. Thus, we were confident in our clinical diagnoses of AD and other dementias.

We excluded 68 of the 140 recruited healthy elderly control subjects because the neurologic and neuropsychologic examination indicated some form of intellectual impairment, and 13 others were excluded because of inadequate family history. The remaining 59 healthy elderly subjects formed the healthy elderly group (HEG).

### Demographics

The patients with probable AD and the HEG were similar in age, and both were significantly older than the PCG. The AD and the PCG differed in education, but there was no difference in education between the patients with AD and the HEG. The probable AD and HEG cohorts had a similar mean number of first-degree relatives per family, but the PCG had fewer first-degree relatives than the healthy elderly subjects. Each of these results are presented in Table 3.

### Dementia in First-Degree Relatives

The relatives of patients with probable AD group were significantly older, which resulted in a greater number of lifetime years at risk than the relatives of either the PCG or the HEG. The number of demented first-degree relatives was significantly higher for the patients with probable AD; there was no difference between the other two groups as is indicated in Table 4.

The estimated odds ratio was compared between groups using logistic regression to adjust for the difference between groups in mean age for first-degree relatives (Table 3). The adjusted odds associated with dementia in first-degree relatives of the patients with probable AD was six times that of the first-degree relatives of the HEG.
but only 1.6 times that of the relatives of the PCG. Because the confidence interval included 1, the odds ratio was not significantly different for the comparison between relatives of patients with probable AD and PCG. When the PCG was divided into those with and without dementia, the adjusted odds ratio associated with dementia in the first-degree relatives of the patients with probable AD was still no different than that calculated for the relatives of either portion of the PCG (demented and nondemented).

Because there was no difference between these two groups of first-degree relatives (AD and PCG), we evaluated the possibility of a type II error. Assuming the log odds ratio for this comparison was the same as that seen in AD vs HEG analysis (log odds ratio = 1.8, SE = 0.3) and an α level of .05, we calculated the power of the test to be 99%. Thus, the likelihood of a type II error in accepting no difference in odds ratios between first-degree relatives of patients with AD and those of the PCG was less than 1%. The adjusted odds ratios were also calculated for the demented and nondemented subjects in the PCG and compared with the HEG as noted in Table 5. The odds of dementia in the relatives of the demented PCG was six times that of the HEG. The odds of dementia in the relatives of the nondemented PCG was four times that of the HEG.

Product-limit survival analysis was used to estimate the cumulative incidence of dementia in first-degree relatives of the three groups. Cumulative incidence of dementia in the three groups increased with age as illustrated in the Figure. By age 91 years, 50% of the first-degree relatives of the probable AD group were considered demented. However, by the same age only 20% of the first-degree relatives of the HEG had developed dementia. Remarkably, by age 91 years, nearly 40% of the first-degree relatives of the PCG were considered demented. The cumulative incidence of dementia in the first-degree relatives of patients with AD and the PCG was significantly higher than that in the HEG (log rank test $x^2 = 27.48, P < .001$). The cumulative incidence in these two groups (AD and PCG) did not differ statistically.

**COMMENT**

Our data confirm earlier studies indicating increased risk of dementia in the first-degree relatives of patients with AD when compared with the first-degree relatives of their healthy peers. However, we have also found that other neurologic disorders, even those without dementia, may be associated with almost the same degree of risk to their first-degree relatives. The odds for dementia in the first-degree relatives of patients with AD and the demented patients in the PCG were both six times that for relatives for the HEG after adjusting for age differences. Even the relatives of the non-demented members of the PCG had four times the risk of the relatives of the HEG.

There are two major issues to consider in the interpretation of our results: validity, which includes selection and information bias, and specificity.

**Selection Bias**

Most case-control studies, except for the population-based study of Hofman et al., have identified patients with AD who voluntarily attend a hospital or clinic and have then recruited a healthy individual to represent a comparison cohort. Patients, or their family members in the case of AD or another dementia, may remember their family history better than the recruited healthy elderly persons resulting in what Rocca and Amaducci termed an awareness bias. A family history of dementia would be a strong motive for seeking medical advice, and would increase the possibility of identifying heredity as a risk factor. Thus, the increased risk in many of the case-control studies of AD could be due to the selection of families with an enhanced knowledge of their family history. The relatives of our PCG may have been influenced by this same bias. Selection bias may also help to explain runover.
why the risk exceeded 50% in some AD families in another study by Farrer et al, although the risk in excess of 50% was interpreted as an indication of an associated environmental factor.

We were unable to obtain family history data from 15% of the PCG and 18% of the HEG compared with 3.5% of the AD group, which could lead to an awareness bias. The inability to obtain information about some of the first-degree relatives in two of the groups could result in a differential misclassification of cases in these families and might lead us to reject or favor the "null hypothesis" of no difference in risk to first-degree relatives of patients with AD. However, this would not explain the difference in risks for relatives between these two comparison groups. Although differential bias may have been present in the comparison of AD with the HEG, we believe that our use of a cohort of patients attending the same clinic lessened the impact of awareness bias among control subjects.

Information Bias

A second, separate family history interview was not performed by us, but we consider the data quality to be as valid as that collected by others because our interview format was similar. As in all previous studies, and ours, information was obtained in interviews with other family members. Few "affected" family members have actually been examined in these studies. Questionnaires and structured interviews can improve reliability of responses, but not the validity. It is difficult to obtain postmortem data or even accurate medical records about dementia in first-degree relatives who have died. Hofman et al obtained and examined medical records and many of the secondary cases had had autopsy confirmation. Those results confirmed, and to some degree validated, the increased risk to relatives of patients with AD in studies where this is not possible. Farrer et al used a weighted scale to increase accuracy of information regarding probands and first-degree relatives, but may have underestimated the number of secondary cases. Without a specific examination of patients or a tissue diagnosis all studies are open to information bias, the magnitude of which depends on the reliability of the informants. Because we were able to obtain data concerning risk in first-degree relatives of patients with AD similar to that in other studies by our method, we assume that the data obtained from the relatives of the HEG and the PCG were equally valid.

Specificity

Other neurologic disorders can be familial. Farrow and colleagues used patients with Parkinson's disease as a comparison group for AD, but found no difference in risk of dementia in first-degree relatives of these two groups. However, because both Hofman et al and Marder et al have found dementia and Parkinson's disease to aggregate in first-degree relatives of patients with AD or Parkinson's disease, this lack of difference in risk might have been anticipated. Similarly, we may have introduced this type of problem by using patients with other neurologic disorders as a control group. The lack of difference in risk of dementia to first-degree relatives in the study by Farrer et al and our own, could also indicate that the increased risk of dementia in first-degree relatives is not specific to AD and may be present in a number of neurologic diseases.

We did not attempt to estimate age at onset of dementia in the relatives because so few informants could provide that information. Farrer et al "censored" this type of age estimate, noting that such estimates increase the age at onset. Although our approach was nondifferential to group, estimating the correct age at onset would result in a shift of the cumulative risk curve to the left by as much as 8 years. A review of the Figure, based on this left shift, would not alter our observations regarding the similarity in risk between the AD and PCG relatives, but would have the effect of lowering the age at which risk approaches 50%.

We were cautious in our interpretation of the maximum estimates of cumulative risk from our data. Maximum estimates from cumulative incidence curves produce large standard errors as is indicated in our figure, particularly for the very old ages where the number of survivors diminish. Thus, beyond the age of 90 years, maximum estimates may not be as accurate.

We have found that issues of validity and specificity have considerable impact on the interpretation of cumulative risk and the calculation of odds ratios in the first-degree relatives of these patients. While our data do not lessen the likelihood that heredity plays a role in the cause of AD, they do imply that other forms of dementia and other cognitive disorders can produce similar risks in first-degree family members. Therefore, other risk factors must be investigated in the cause of AD.

This work was supported by federal grants, AG07252, NS26179, RR0435, the Charles S. Robertson Memorial Gift for Alzheimer's disease, and federal grant PO-50-AG-08702 to the Center for Alzheimer's Disease Research in New York City (NY).

We thank Allan Hauser, MD, Karen Marder, MD, and Ruth Ottman, PhD, for their help with the interpretation of our data and assistance with the manuscript.

Analysis showing the cumulative incidence of dementia among first-degree relatives of either patients with Alzheimer's disease, subjects from the patient comparison group, or members of the healthy elderly group. The hatched line indicates relatives of patients with Alzheimer's disease; dotted line, relatives of the patient control group; straight line, healthy elderly subjects' relatives. By the age of 91 years, the cumulative incidence of dementia was 48.7% in the relatives of patients with Alzheimer's disease, but about 36.9% in the patient comparison groups and less than 23% in the relatives of the healthy control subjects.
References


